|
Current Churg
Strauss Syndrome Research
Studies actively recruiting participants.
Mepolizumab
As a Steroid-Sparing Treatment Option in the Churg Strauss Syndrome
Purpose
The purpose of this study is to determine whether Mepolizumab (a
monoclonal antibody against interleukin-5) is a safe and well-tolerated
therapy that will allow for steroid tapering in patients with steroid-dependent
Churg-Strauss Syndrome (CSS).
Contacts
Michael E Wechsler, MD. MMSc
617-732-8202
mwechsler@partners.org
Sophia Kim, MD
617-525-3218
skim48@partners.org
Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Principal Investigator: Michael Wechsler, MD
Association
Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis
Nodosa or Churg Strauss Syndrome
Purpose
To determine whether a combination of corticosteroids and azathioprine
can achieve a higher remission rate and a lower subsequent relapse
rate in patients with newly-diagnosed microscopic polyangiitis,
polyarteritis nodosa or Churg Strauss syndrome with no poor prognosis
factor (FFS=0), and without significantly increasing the rate of
adverse events, as compared to corticosteroids alone.The study hypothesis
is a reduction of the absolute risk of treatment failure or relapse
within the first 24 months following initiation of therapy of least
25%.
Contacts
Loic Guillevin, MD, PhD
0033158411321
loic.guillevin@cch.aphp.fr
Christian Pagnoux, MD
0033158411461
christian.pagnoux@cch.aphp.fr
Locations
France
Hopital Cochin Pôle de Médecine UF Médecine
Interne
Paris, France, 75014
Principal Investigator: Loic Guillevin, MD, PhD
Sub-Investigator: Christian Pagnoux, MD
Rituxan
in Churg Strauss Syndrome
Purpose
A pilot, open label study using 4 weekly doses of Rituximab in the
treatment of CSS with renal involvement.
Locations
Mayo Clinic
Rochester, Minnesota, United States, 55905
Contact:
Fernando C. Fervenza, M.D., Ph.D. 507-266-7961
fervenza.fernando@mayo.edu
Principal Investigator: Fernando C Fervenza, M.D., Ph.D.
Determining
Disease Activity Biomarkers in Individuals With Churg-Strauss Syndrome
Purpose
Churg-Strauss Syndrome (CSS) is a rare immune system disorder that
causes asthma, an excessive number of eosinophils (a type of white
blood cell) in the blood, and the inflammation of blood vessels,
or vasculitis. In order to properly treat CSS, it is critical that
the level of disease activity can be determined over the course
of the disease. The purpose of this study is to determine new biological
markers, or biomarkers, that may be used to assess the severity
of this disease in people with CSS.
Locations
1) The Johns Hopkins Vasculitis Center
Baltimore, Maryland, United States, 21224
Contact
Cynthia Bethea 410-550-4390
cbethea3@jhmi.edu
Principal Investigator: Philip Seo, MD, MHS
2) Boston University School of Medicine
Boston, Massachusetts, United States, 02118
Contact
Carol King 617-414-2505
caking@bu.edu
Principal Investigator: Peter A. Merkel, MD, MPH
3) Mayo Clinic
Rochester, Minnesota, United States, 55905
Contact
Kathy Mieras 507-284-9187
caking@bu.edu
Principal Investigator: Ulrich Specks, MD
Principal Investigator: Steven R. Yetterberg, MD
United States, Ohio
4) Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Contact
Katherine Tuthill 216-444-5257
TUTHILLK@ccf.org
Principal Investigator: Carol A. Langford, MD, MHS
5) Mount Sinai Hospital
Toronto, Ontario, Canada
Contact
Sara Webster 416-586-8616
swebster2@mtsinai.on.ca
Principal Investigator: Simon Carette, MD
6) St. Joseph's Healthcare
Hamilton, Ontario, Canada
Contact
Sandra Messier 905-522-1155 ext 35873
smessier@stjoes.ca
Principal Investigator: Nader A. Khalidi, MD
Anti-Interleukin-5
(IL-5) Study for Hypereosinophilic Syndrome
Purpose
The purpose of the study is to assess the toxicity of anti-IL-5,
and to see whether it lowers peripheral blood eosinophils and/or
tissue and whether it has a steroid and/or interferon sparing effect.
Contacts
Bridget K Buckmeier, BA
513-636-5540
bridget.buckmeier@cchmc.org
Locations
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229-3039
Principal Investigator: Marc E Rothenberg, MD, Ph.D.
Abatacept
in ANCA Associated Vasculitis
Purpose
The purpose of this study is to investigate whether abatacept can
prevent relapse in patients with ANCA associated vasculitis(AAV).
This is a randomised double blinded placebo controlled trial.
Contacts
Alan Salama 02083833980
a.salama@imperial.ac.uk
Karen Mosley 02083833936
k.mosley@imperial.ac.uk
Locations
Imperial College London, Hammersmith Hospital
London, United Kingdom, W12 0NN
Principal Investigator: Alan Salama
Hematopoietic
Stem Cell Support in Vasculitis
Purpose
The systemic vasculitis is a wide-ranging group of diseases that
are characterized by the presence of blood vessel inflammation (1).
Despite this common feature, each type of vasculitis has a unique
variety of clinical manifestations that influences its degree of
disease severity and ultimately its management. Immunosuppressive
therapy forms the foundation of treatment for almost all forms of
systemic vasculitis.
The systemic necrotizing vasculitis (SNV) are a subset of vasculitis
with significant morbidity and mortality (2). The SNV are Wegener's
granulomatosis, allergic angiitis and granulomatosis (AAG) (also
known as Churg-Strauss syndrome), polyarteritis nodosum (PAN), microscopic
polyangiitis (MPA), and overlap syndrome. In spite of modern therapeutic
immune suppressive agents, there remains a not inconsequential morbidity
and mortality associated with SNV. The current standard therapy
for SNV is chronic oral cyclophosphamide (1-3 mg/kg/day) and corticosteroids
(3-6). Transplant doses of cyclophosphamide at 200 mg/kg infused
over 4 days is the most common worldwide transplant regimen for
systemic lupus erythematosus (SLE) (7). Like SLE, SNV are cyclophosphamide
responsive disease. We, therefore, propose a trial of high dose
cyclophosphamide with anti-thymocyte globulin (ATG) for patients
with SNV.
Contacts
Dzemila Spahovic, MD 312-908-0059
d-spahovic@northwestern.edu
Locations
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States, 60611
Principal Investigator: Richard Burt, MD
Sub-Investigator: Yu Oyama, MD
Sub-Investigator: Kathleen Quigley, RN
Sub-Investigator: Kimberly Yaung, RN
Identifying genetic causes of CSS
Purpose
Blood samples from CSS patients will be analyzed for specific mutations and compared with DNA from people without CSS. While all CSS patients are eligible, Dr Wechsler is particularly interested in identifying patients who have relatives with CSS or related disease such as asthma, vasculitis, autoimmunity. He is hoping to ultimately identify a gene that may be playing a role in causing CSS.
Contacts
Michael E Wechsler, MD. MMSc
617-732-8202
mwechsler@partners.org
Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Principal Investigator: Michael Wechsler, MD
|
